



 [Update Your Profile](#)

Ronald B. Gartenhaus, MD

Academic Title:

Professor

Primary Appointment:

Medicine

Additional Title:

Secondary Appt: Joint Program in Biochemistry & Molecular Biology; Co-Leader, Program in Molecular & Structural Biology of the Greenebaum Cancer Center; Head, Baltimore VA Hematologic Malignancies Clinic; Member, Combined MD/PhD Committee

Email:

rgartenhaus@som.umaryland.edu

Location:

Bressler Research Building, Room 9-011

Phone (Primary):

(410) 328-3691

Fax:

(410) 328-6559

[Download CV](#)

Education and Training

1977 B.A. State University of New York at Albany, New York

1981 M.D. Universidad del Noreste, Tampico, Mexico

Post Graduate Training

1981-1982: Fifth Pathway Internship Long Island Jewish-Queens Hospital Center State University of New York at Stony Brook, NY

1982-1985: Internship & Residency in Internal Medicine University Hospital State University of New York at Stony Brook, NY

1985-1987: Fellowship in Medical Oncology M.D. Anderson Hospital and Tumor Institute Houston, Texas

1987-1988: IRTA Fellow National Cancer Institute (NCI), National Institutes of Health (NIH) Laboratory of Cellular and Molecular Biology Bethesda, Maryland

1988-1990: IRTA Fellow National Cancer Institute (NCI), National Institutes of Health (NIH) Laboratory of Tumor Cell Biology (LTCB) Bethesda, Maryland

1990-1992: Senior Staff Fellow, National Cancer Institute (NCI), National Institutes of Health (NIH) Laboratory of Tumor Cell Biology Bethesda, Maryland

1992: Guest Researcher National Cancer Institute (NCI), National Institutes of Health (NIH) Laboratory of Tumor Cell Biology Bethesda, Maryland

Biosketch

Ronald B. Gartenhaus, M.D. is a Tenured Professor of Medicine and Co-Leader, Program in Molecular & Structural Biology at the NCI-designated University of Maryland Marlene and Stewart Greenebaum Cancer Center. He also supervises the Hematologic Malignancies Clinic at the University affiliated Baltimore VA Hospital. Dr. Gartenhaus has a longstanding interest in lymphoma biology dating back to the early 1990's when he trained as a post-doc in the laboratory of Dr. Robert Gallo at the National Cancer Institute after completing a medical oncology fellowship at the MD Anderson Cancer Center. His laboratory was the first to identify and describe the MCT-1 oncogene. His current research focus is studying post-transcriptional/translational gene deregulation as well as oncogenic signaling cascades associated with lymphoma and how they can be exploited for targeted therapy. His research has been continually funded over the past 15 years through multiple NIH grants, VA Merit Review awards, as well as other national research foundations. Dr. Gartenhaus is a standing member of the NIH MONC study section and has participated as an ad hoc member of multiple NIH and VA reviews, including several NIH PO1 program project review panels. He has served on multiple editorial boards and is currently an Associate Editor for PLOS Genetic.

Positions and Professional Experience

1981 - 1982 Fifth-Pathway, Long Island Jewish-Queens Hospital Center, State University of New York at Stony Brook, Stony Brook, NY

1982 - 1983 Internship in Internal Medicine, University Hospital, State University of New York at Stony Brook, Stony Brook, NY

- 1983 - 1985 Residency in Internal Medicine, University Hospital, State University of New York at Stony Brook, Stony Brook NY
- 1985 - 1987 Fellowship, Medical Oncology, M.D. Anderson Hospital & Tumor Institute, Houston, TX
- 1987 - 1988 IRTA Fellow, Laboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1988 - 1990 IRTA Fellow, Laboratory of tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1990 - 1992 Senior Staff Fellow, Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1992 Guest Researcher, Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1993 - 1996 Assistant Professor of Medicine, Albert Einstein College of Medicine, Bronx, NY
- 1993 - 1996 Assistant Attending Physician, Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY
- 1996 - 1999 Associate Professor and Section Chief, Molecular Oncology, MCP Hahnemann School of Medicine, Philadelphia, PA
- 1999 - 2004 Associate Professor of Medicine, Northwestern University Medical School
- 2000 - 2004 Co-Director, Hematologic Malignancies Research Program of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University
- 2004 - present Associate Professor of Medicine, University of Maryland Medical School
- 2004 - present Member, Program in Molecular and Structural Biology of the University of Maryland Marlene and Stewart Greenebaum Cancer Center
- 2007 - present Head, Hematological Malignancies Clinic, Baltimore VA
- 2009 - present Co-Leader, Program in Molecular & Structural Biology of the University of Maryland NCI-Designated Marlene and Stewart Greenebaum Comprehensive Cancer Center
- 2010 Tenure awarded
- 2012 - present Professor of Medicine, University of Maryland Medical School

Research/Clinical Keywords

Molecular & Structural Biology, Lymphoma biology, Post-transcriptional/translational gene deregulation, Oncogenic signaling cascades associated with lymphoma and how they can be exploited for targeted therapy

Highlighted Publications

Krystyna Mazan-Mamczarz, Frank Zhao, Bojie Dai, James Steinhardt, Kimberly Berk, Ari Unger, Mariola Sadowska, Yonqing Zhang, Elin Lehrmann, Kevin Becker, Rita Shaknovich, Zhenqiu Liu, **Ronald B. Gartenhaus**. Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. *PLoS Genet* 10(1): e1004105. doi:10.1371. 2014

James J. Steinhardt, Raymond J. Peroutka, Krystyna Mazan-Mamczarz, Qing Chen, Simone Houg, Carol Robles, Rolf Barth, Joseph Dubose, Brandon Bruns, Ronald Tesoriero, Deborah Stein, Ryan Shakley, Raymond Fang, Kevin Jones, Nader Hanna, Jason Pasley, Carlos Rodriguez, David Kligman, Matthew Bradley, Joseph Rabin, Stacey Shakleford, Bojie Dai, Ari L. Landon, ThomasScalea, Ferenc Livak and **Ronald B. Gartenhaus**. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. *Blood*. Dec 11:3758-67. 2014

Ari Landon, Parameswary A. Muniandy, Krystyna Mazan-Mamczarz, Simone Houg, Bojie Dai, James Steinhardt, RJ Peroutka, Katherine Borden and **Ronald B. Gartenhaus**. MNKS regulate an eIF4E1-eIF4E3 translation 'switch' to modulate oncogenic translation in DLBCL. *Nature Communication*, Nov 18; 5:5413. 2014

Bojie Dai, Raymond J. Peroutka, Simone Houg, Parameswary A Muniandy, Yonqing Zhang, Elin Lehrmann, Krystyna Mazan-Mamczarz, James Steinhardt, Ari Landon, Mikhail Shlyak, Qing Ching Chen, Kevin Becker, Rohit Talwani, **Ronald B. Gartenhaus**. Hepatitis C virus up-regulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. *Oncogene*. Jun 9;35(23):2979-90. 2016

Bandish Kapadia, Nahid Nanaji , Kavita Bhalla , Binny Bhandary, Rena Lapidus, Afshin Behesti, Andrew Evens and **Ron Gartenhaus**. FASN induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. *Nature Communication*, in press

Kavita Bhalla, Susan Jaber, Nanaji Nahid M, Karen Underwood, Afshin Beheshti, Ari Landon, Binny Bhandary, Paul Bastain, Andrew M. Evens, John Haley, Brian Polster, and **Ronald B. Gartenhaus**. Selective translation of HK2 during hypoxia promotes growth of DLBCL. *Scientific Reports*, 2017 in press

 [Update Your Profile](#)